Two
of Expression Pathology's key patents covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection
have
issued
Gaithersburg,
MD. May 19, 2008: Expression Pathology Inc. (EPI), a leader
in tissue protein analysis, announced that two key patents
have issued covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection.
A
proprietary laser-activated energy transfer coating on standard
glass slides allows precise, convenient and automatable non-contact
microdissection of specific cell types from tissue. Current
methods employ plastic films or adhesives which require direct
contact with the tissue. They must be cut or activated along
with the tissue, limiting speed and automation and introducing
potential contaminants. By contrast, DIRECTOR™ Slides
make possible rapid, non-contact harvesting of even the finest
cellular features. They are compatible with existing laser
microdissection instruments available from Leica and Zeiss
and suitable for genomic and proteomic applications.
An
Issue Notification has been received for U.S. patent number
7,381,440 titled Biological Printing for Tissue Microdissection
Via Indirect Photon-Biomaterial Interactions, issued to the
U.S. Naval Research Laboratory. Two of EPI’s founders
are co-inventors and EPI has exclusive worldwide rights to
tissue research and diagnostics applications. This complements
EPI’s rights to another patent covering this technology,
U. S. patent number 7,294,367 issued to the U.S. Naval Research
Laboratory November 13, 2007.
“ These
patents, together with our Liquid Tissue® technology for
solubilizing the protein content of tissue, are integral to
our tissue proteomics strategy for discovery and measurement
of proteins in tissue,” said Casey Eitner, EPI’s
president and chief executive officer. “Pathologist-directed
automated microdissection is a key part of our platform to
enable the use of mass spectrometry for analysis of proteins
in routine patent biopsies and surgical tissue, a $1.2 billion
market.”
DIRECTOR™ slides
bring a whole new level of speed and accuracy to laser microdissection,
allowing collection directly into a vial, while eliminating
the need for plastic membrane-coated slides or sticky caps.
These membrane-free slides employ a proprietary energy transfer
coating bonded to a glass support. UV-laser energy is converted
to kinetic energy upon striking the energy transfer coating,
vaporizing it, thereby propelling selected features into the
vial. The laser energy is absorbed by the coating so sensitive
molecules such as RNA or DNA are not damaged.
DIRECTOR™ slides
are inert to a wide range of chemical and thermal conditions.
They can be autoclaved, and are stable in organic solvents
such as xylenes. The slides can be rendered sterile or RNase-free
with any standard method. They show no autofluorescence and
are optically neutral, making them ideal for applications requiring
fluorescent stains, as well as applications requiring DIC or
polarized light.
About
Expression Pathology Inc.
EPI
is developing proprietary cancer tests and research tools to
study and measure proteins in formalin-fixed paraffin-embedded
(FFPE) tissue, the format of patient tissue routinely collected
and stored in medical treatment and research facilities. FFPE
tissue constitutes a huge untapped resource for discovery,
validation and measurement of valuable biomarkers of disease
progression, drug response and toxicity.
EPI’s
Liquid Tissue® sample preparation and DIRECTOR™ laser
microdissection technologies enable mass spectrometry-based
discovery and measurement of proteins in FFPE tissue. EPI offers
these as research products, contract services and collaborative
research programs. For more information, see www.expressionpathology.com.
Expression
Pathology Inc.
Peter Tunon, Vice President Sales and Marketing
9290 Gaither Road
Gaithersburg, MD 20877
Phone: (301) 977-3654
E-mail: p.tunon@expressionpathology.com
American Association
of Cancer Research, San Diego, April 12-16.
(link)
Booth 2428. See three posters using our technology;
discovery of endometrial cancer markers (abstract), metastasis marker in melanoma (abstract
), protein biomarkers relating to metastasis
and disease progression in lung cancer (abstract).
US and Canadian Association
of Pathology, Denver, Mar. 1-7: Application
of a Global Proteomic Approach to Archival Precursor
Lesions: Upregulation of DMBT-1 and TG2 in Pancreatic
Cancer Precursors (link)
Soc.
of Surgical Oncology, Chicago, Mar. 13-16: Identification
of Prognostic Biomarkers in Patients with Resectable
Pancreas Cancer Using Formalin-fixed Tissue, Marcus
Tan, MD, Washington University School of Medicine,
St. Louis, MO (link)
SUBSCRIBE
to our mailing list : stay informed about
news and events in tissue proteomics.
Expression
Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible mass spec
protein analysis of formalin-fixed tissue,
enabling discovery, validation and routine
measurement of protein biomarkers related to clinical outcomes.
Our near-term mission is
to offer breakthrough research tools and
collaborations to improve drug and diagnostic development
and for basic research. Our proprietary
technologies also provide the foundation
for a whole new platform of tissue diagnostic tests currently
under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures
the entire protein content. Mass spec friendly. Requires
only 30,000 cells for multiple
mass spectrometry analyses.
The Director™ Laser
Microdissection Slides provide the fastest, easiest
and most accurate way to collect specific
cellular features from tissue sections. Engineered
for use with existing Leica LMD and PALM Zeiss laser
microdissection system.